September 4th 2024
Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.
April 11th 2024
Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.
March 11th 2024
Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.
December 7th 2023
Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.
September 19th 2023
Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.
August 17th 2023
Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.
August 10th 2023
Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.
Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.
August 3rd 2023
Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.
Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.
July 27th 2023
Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.
Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.
July 20th 2023
Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.
Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.
July 13th 2023
Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.
Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.
July 6th 2023
Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.
Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.
June 29th 2023
Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.
Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.